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Genetic counseling can be seen as the health professional 
role concerned with the impact of genetic disease and 
genetic  information  on  individuals  and  families.  It  has 
been predominantly concerned with the human problems 
arising in the context of single gene disorders, chromo­
some  rearrangements  and  malformation,  including 
syndromes of neurodevelopmental disturbance and dys­
morphic physical features. These are the core conditions 
dealt with in genetic counseling practice on both sides of 
the  North  Atlantic,  although  the  scope  of  genetic 
counseling  does  vary  between  countries  so  that,  for 
example, North American genetic counselors are often 
heavily engaged in the offer of routine antenatal screening 
to pregnant women, whereas this is not standard practice 
in Europe. As genomic analysis enters clinical medicine 
[1,2], it is timely to reflect on the impact that this will 
have on genetic counseling practice [3]. Instead of merely 
single gene test results, will genetic counselors undertake 
risk counseling for the common, complex disorders on 
the  basis  of  pan­genome  test  results  such  as  genome­
wide single nucleotide polymorphism (SNP) panels, array 
comparative  genome  hybridization  studies  of  copy 
number  variants,  exome  sequencing  or  full  genome 
sequence? If they do, what impact will this have on the 
prevention  and  treatment  of  the  chronic  diseases  that 
seem likely to be the major health problems of the 21st 
century?
For now, no reputable professional ­ genetic counselor 
or other clinician ­ is using SNP array results in relation 
to  complex  diseases  as  the  basis  of  health  care  inter­
ventions or to support recommendations about lifestyle: 
the validity of such interpretations is insufficiently robust 
and there has been no demonstration of clinical utility 
[4,5].  However,  once  genome  sequencing  is  widely 
available and readily affordable, many of the obstacles to 
the demonstration of validity will (eventually) disappear, 
although  it  will  take  time  for  the  clinical  research 
community to develop confidence in the interpretation of 
the  accumulating  data.  At  that  point,  whenever  that 
comes  to  pass,  will  genetic  counselors  embrace  the 
genomics of complex disease as well as the genetics of 
Mendelian disease?
Our answer is a Yes and a No and a Maybe.
Yes
The principal clinical application of genome sequencing 
has so far been the recognition of ‘new’ Mendelian loci 
responsible either for previously unrecognized disorders 
or  for  additional  loci  contributing  to  known  clinical 
entities. As the cost of genome sequencing approaches 
the cost of mutation searching in multiple loci associated 
with a disease presentation, such as hypertrophic cardio­
myopathy  or  retinitis  pigmentosa,  genome  sequencing 
will be performed because it will be a cheaper means to 
resolve  the  locus  heterogeneity  or  to  distinguish  the 
unusual Mendelian forms of a common disease from the 
much more frequent sporadic cases. The clinical applica­
tion will be driven by a Mendelian logic: even conser  va­
tive and cautious genetic counselors will use such infor­
mation  gratefully  as  it  will  allow  them  to  give  useful 
answers  to  their  patients  and  their  patients’  relatives 
more frequently and more rapidly.
There will, however, be a less clearly useful ­ and less 
welcome ­ spate of information to flow from the genome 
sequencers.  Alongside  the  information  that  is  actively 
sought and desired because it is of practical relevance, 
there will be information of uncertain significance. First, 
there will be nonsense and frameshift mutations in the 
coding regions of ‘important’ loci previously associated 
with a disease phenotype. There will also be information 
about the less common copy number variants (CNVs), 
whose significance may depend on gene­by­gene inter­
actions, such as those applicable in development that led 
to the ‘two hit’ model of developmental disruption. There 
will be SNP data of possible but dubious relevance to the 
common  complex  disorders,  and  data  about  variation 
able to modify the phenotype of ‘Mendelian’ disorders. 
There will inevitably also be other, emergent findings and 
applications of such data. © 2010 BioMed Central Ltd
‘Genomic counseling’? Genetic counseling in the 
genomic era
Angus Clarke1* and Katie Thirlaway2
MUSINGS
*Correspondence: clarkeaj@cardiff.ac.uk 
1Institute of Medical Genetics, School of Medicine, Cardiff University, Heath Park, 
Cardiff CF14 4XW, UK 
Full list of author information is available at the end of the article
Clarke and Thirlaway Genome Medicine 2011, 3:7 
http://genomemedicine.com/content/3/1/7
© 2011 BioMed Central LtdIt is going to take years for us to interpret such variants 
with confidence. The question will be raised as to whether 
‘difficult to interpret’ information should be released at 
all or only the information specifically sought. We do not 
think  that  restricting  the  release  of  information  about 
sequence variants will be a sustainable position ­ and it 
may be unhelpful in retarding the development of our 
collective  genome­interpreting  skills  ­  but  in  the  short 
term it may be an attractive transitional strategy.
Our  ‘Yes’,  therefore,  is  a  recognition  that  genetic 
counselors will have to deal with the interpretation of 
genomic information relating to the risk of the common 
complex diseases simply because the information will be 
there and it would be unreasonable to ignore it. So our 
Yes is uttered in a somewhat reluctant, resigned voice. 
Much of this will be a distraction from the real work of 
answering  the  questions  that  counselors  have  been 
asked  and  giving  the  information  in  which  they  have 
real confidence.
No
But will genetic counselors engage with genomic infor­
mation  relating  to  complex  diseases  with  the  goal  of 
inter  preting  it  for  the  ‘(wo)man  in  the  street’,  in  the 
absence of a relevant family history and simply as a basis 
for making lifestyle and health screening decisions? Here, 
we  think  the  answer  will  be  No  ­  for  several  reasons. 
First, whereas genetic counselors are well trained to help 
individuals and families tackle decisions about predictive 
testing, prenatal testing and family communication in the 
face of large (Mendelian) risks, their skills will not be so 
relevant when families confront complex genomic infor­
ma  tion, for which ‘predictive’ testing is not available and 
when the applicability of the information for reproductive 
decisions and family communication is small. However, 
although  they  might  be  clinically  trivial,  the  role  that 
perceived genetic risk could have in adherence to preven­
tion and treatment has the potential to be important and 
is currently not well understood. There is a commonly 
held clinical view that information about ‘genetic risk’ has 
the potential to improve compliance but, in fact, there is 
evidence  that  understanding  a  risk  to  have  a  genetic 
etiology has little or no impact on adherence to preven­
tative and treatment strategies [6].
However, this territory ­ decisions about lifestyle and 
about appropriate participation in population screening 
programs ­ is that of primary health care professionals, 
who  are  established  on  a  scale  appropriate  to  the 
challenge, whereas genetic counselors are far too few. It 
seems unlikely that it will be very useful in the short term 
to  apply  genomic  investigations  to  risk  prediction  for 
coronary artery disease [7] and other vascular disorders 
at the population level; this adds little to the predictions 
of  disease  risk  from  simple  endophenotypes,  such  as 
blood  pressure,  serum  cholesterol  and  the  body  mass 
index. Genetic counselors, however, do have an impor­
tant role in educating primary health care practitioners 
and  advising  on  appropriate  criteria  for  referral  of 
families to genetic services.
Finally, genetic counselors may choose not to become 
engaged in ‘genomic health risk’ assessments, in that the 
style of support they usually provide in making decisions 
differs fundamentally from that appropriate here. Genetic 
counselors usually help clients to weigh up the personal 
and family consequences of particular decisions, whereas 
‘genomic health risk assessments’ will have to focus their 
attention  much  more  on  promoting  or  achieving  the 
desired  behavioral  changes.  The  genomic  health  risk 
assessment may indicate specific personal targets for the 
intake  of  certain  foods  ­  especially  vitamins  or  other 
micronutrients ­ but for most people the recommended 
diets  and  lifestyles  will  be  much  the  same  even  if  the 
strength of the evidence underlying the lifestyle prescrip­
tion  may  differ  in  detail  between  individuals.  It  seems 
from the limited evidence available that the endorse  ment 
of lifestyle advice by gene­based analyses gives recom­
mendations about lifestyle little additional weight [8] and 
may raise troublesome processes of adjustment [9]. That 
leads  to  the  question  of  whether  the  accumulation  of 
genetic  and  clinical  data  in  gene  databanks  will  prove 
helpful in permitting the dissection of behavioral propen­
sity to exacerbate risk from the underlying physiological 
or metabolic predisposition to the disease. Will it prove 
helpful  ­  even  if  it  is  possible  ­  to  tease  apart  these 
entangled and interacting variables?
Maybe…
We are tempted to imagine that discrimination between 
the  genetic  basis  of  a  behavioral  propensity  and  a 
physiological  predisposition  to  disease  will  have  little 
clinical application, particularly while behavioral adapta­
tion remains the best preventative strategy. If a person is 
predisposed  to  disease,  at  least  in  part  because  of  a 
predisposition to behave in an ‘unhealthy’ manner, then 
there is great potential for awareness of the behavioral 
propensity to interact with the propensity itself in making 
future  decisions.  How  this  interaction  will  play  out  is 
unknown  but,  given  the  well  established  role  of  self 
efficacy in successful behavioral change, it could easily 
undermine attempts to change [10]. Alternatively, such 
genetic information might lead to a better understanding 
of the difficulties an individual is facing and so perhaps to 
better­tailored intervention strategies. If asked whether 
such genome­wide information about behavioral propen­
sities will be helpful in practice, alongside information 
about  physiological  and  metabolic  propensities,  we 
answer ‘Maybe’ because the outcome of such self­aware 
processes  of  interaction  cannot,  even  in  principle,  be 
Clarke and Thirlaway Genome Medicine 2011, 3:7 
http://genomemedicine.com/content/3/1/7
Page 2 of 3computed. Any attempt to predict the outcome of such 
interactions  across  such  a  diverse  range  of  complex 
conditions would be unwise and appear naïve.
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